NYSE:PEN

Penumbra (PEN) Stock Forecast, Price & News

$233.02

+0.33 (+0.14%)

(As of 09:39 AM ET)

Compare

Today's Range: $233.02
▼
$233.84
50-Day Range: $232.79
▼
$308.03
52-Week Range: $144.76
▼
$348.67

Volume: 2,185 shs
Average Volume: 353,900 shs
Market Capitalization: $8.96 billion

P/E Ratio: 314.89
Dividend Yield: N/A
Price Target: $319.00

Penumbra MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.85 Rating Score
Upside/Downside: 37.0% Upside
$319.00 Price Target
Short Interest: Bearish
5.83% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.33
Upright™ Environmental Score
News Sentiment: 0.91
Based on 9 Articles This Week
Insider Trading: Selling Shares
$9.01 M Sold Last Quarter
Proj. Earnings Growth: 56.65%
From $1.73 to $2.71 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

91st out of 966 stocks

Surgical & Medical Instruments Industry

17th out of 95 stocks

4.4

Analyst's Opinion

Consensus Rating
Penumbra has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $319.00, Penumbra has a forecasted upside of 37.0% from its current price of $232.79.
Amount of Analyst Coverage
Penumbra has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.83% of the outstanding shares of Penumbra have been sold short.
Short Interest Ratio / Days to Cover
Penumbra has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Penumbra has recently increased by 1.82%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Penumbra does not currently pay a dividend.
Dividend Growth
Penumbra does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Penumbra has received a 46.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Surgical instruments" product. See details.
Environmental Sustainability
The Environmental Impact score for Penumbra is -1.33.

3.3

News and Social Media Coverage

News Sentiment
Penumbra has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Penumbra this week, compared to 4 articles on an average week.
Search Interest
Only 10 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
5 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,013,246.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Penumbra is held by insiders.
Percentage Held by Institutions
88.18% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Penumbra are expected to grow by 56.65% in the coming year, from $1.73 to $2.71 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Penumbra is 314.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 113.01.
Price to Earnings Ratio vs. Sector
The P/E ratio of Penumbra is 314.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 105.90.
Price to Book Value per Share Ratio
Penumbra has a P/B Ratio of 8.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

PEN Price History

30 days | 90 days | 365 days | Advanced Chart

PEN Stock News Headlines

October 3, 2023 | msn.com

Citigroup Maintains Penumbra (PEN) Buy Recommendation

October 3, 2023 | americanbankingnews.com

Penumbra (NYSE:PEN) PT Lowered to $320.00 at Citigroup

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

September 24, 2023 | markets.businessinsider.com

BTIG Sticks to Their Buy Rating for Penumbra (PEN)

September 20, 2023 | msn.com

Piper Sandler Reiterates Penumbra (PEN) Overweight Recommendation

September 14, 2023 | finance.yahoo.com

Penumbra (PEN): A Modestly Undervalued Gem in the Medical Device Market?

September 14, 2023 | finance.yahoo.com

Insider Sell: Penumbra Inc CEO and President Adam Elsesser Sells 9,666 Shares

September 11, 2023 | finance.yahoo.com

Buy These 3 Low-Beta Stocks to Counter Market Volatility

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

September 8, 2023 | msn.com

Morgan Stanley Initiates Coverage of Penumbra (PEN) with Equal-Weight Recommendation

September 6, 2023 | msn.com

Why did Penumbra stock go up today? Bullish remarks by management

September 6, 2023 | markets.businessinsider.com

Analyst Expectations for Penumbra's Future

September 6, 2023 | finance.yahoo.com

Unveiling Penumbra (PEN)'s Value: Is It Really Priced Right? A Comprehensive Guide

September 1, 2023 | msn.com

Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy

September 1, 2023 | finance.yahoo.com

Wall Street Analysts Believe Penumbra (PEN) Could Rally 27.69%: Here's is How to Trade

August 30, 2023 | finance.yahoo.com

Artisan Partners Small Cap Fund Trimmed Penumbra (PEN) Based on Valuation Discipline

August 28, 2023 | msn.com

Which U.S. states will October's 'ring of fire' solar eclipse be visible from?

August 21, 2023 | finance.yahoo.com

Penumbra (NYSE:PEN) Might Be Having Difficulty Using Its Capital Effectively

August 17, 2023 | msn.com

RBC Capital Reiterates Penumbra (PEN) Outperform Recommendation

August 6, 2023 | markets.businessinsider.com

Penumbra (PEN) Gets a Buy from BTIG

August 4, 2023 | benzinga.com

Check Out What Whales Are Doing With PEN

August 4, 2023 | finance.yahoo.com

Does This Valuation Of Penumbra, Inc. (NYSE:PEN) Imply Investors Are Overpaying?

August 3, 2023 | markets.businessinsider.com

RBC Capital Sticks to Its Buy Rating for Penumbra (PEN)

August 3, 2023 | msn.com

Potential For Accelerated Growth In Penumbra Despite Product Launch Delays: Analysts' Positive Outlook Post Q2 Results

August 3, 2023 | finance.yahoo.com

Penumbra, Inc. (NYSE:PEN) Q2 2023 Earnings Call Transcript

August 2, 2023 | finance.yahoo.com

Q2 2023 Penumbra Inc Earnings Call

August 1, 2023 | washingtonpost.com

Penumbra: Q2 Earnings Snapshot

See More Headlines

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings: 8/01/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:PEN
CUSIP: N/A
CIK: 1321732
Web: www.penumbrainc.com
Phone: (510) 748-3200
Fax: 510-748-3232
Employees: 3,900
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $319.00
High Stock Price Forecast: $376.00
Low Stock Price Forecast: $230.00
Forecasted Upside/Downside: +37.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.85
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.74
Trailing P/E Ratio: 314.57
Forward P/E Ratio: 134.56
P/E Growth: N/A
Net Income: $-2,000,000.00
Net Margins: 3.11%
Pretax Margin: 4.09%
Return on Equity: 3.16%
Return on Assets: 2.33%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 5.74
Quick Ratio: 3.25

Sales & Book Value

Annual Sales: $847.13 million
Price / Sales: 10.56
Cash Flow: $0.78 per share
Price / Cash Flow: 299.23
Book Value: $26.30 per share
Price / Book: 8.85

Miscellaneous

Outstanding Shares: 38,440,000
Free Float: 36,400,000
Market Cap: $8.95 billion
Optionable: Optionable
Beta: 0.57

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Adam Elsesser (Age 61)
Co-Founder, Chairman, Pres & CEO
Comp: $601.62k

Dr. Arani Bose M.D. (Age 61)
Co-Founder & Director
Comp: $37.5k

Ms. Maggie S. Yuen (Age 51)
Chief Financial Officer
Comp: $660.98k

Mr. Lambert Shiu (Age 43)
Chief Accounting Officer
Comp: $539.15k

Ms. Johanna Roberts (Age 51)
Exec. VP, Gen. Counsel & Sec.
Comp: $655.75k

Ms. Lynn Rothman (Age 62)
Exec. VP & Chief Bus. Officer

Mr. Ben Sorci
Exec. VP of Operations

Mr. Pankaj Tiwari
Exec. VP & Chief Information Officer

Ms. Jee Hamlyn-Harris
Investor Relations Officer

Mr. Ben Tompkins
Exec. VP of Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PEN shares.
View PEN analyst ratings or view top-rated stocks.
What is Penumbra's stock price forecast for 2023?: 13 Wall Street research analysts have issued twelve-month price targets for Penumbra's shares. Their PEN share price forecasts range from $230.00 to $376.00. On average, they expect the company's share price to reach $319.00 in the next year. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for PEN or view top-rated stocks among Wall Street analysts.
How have PEN shares performed in 2023?: Penumbra's stock was trading at $222.46 on January 1st, 2023. Since then, PEN shares have increased by 4.6% and is now trading at $232.7850.
View the best growth stocks for 2023 here.
When is Penumbra's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PEN earnings forecast.
How were Penumbra's earnings last quarter?: Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings data on Tuesday, August, 1st. The company reported $0.43 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.15. The firm earned $261.50 million during the quarter, compared to the consensus estimate of $253.59 million. Penumbra had a trailing twelve-month return on equity of 3.16% and a net margin of 3.11%. The firm's revenue for the quarter was up 25.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.01 earnings per share.
What ETFs hold Penumbra's stock?: ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Indxx Medical Devices ETF (MDEV), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), First Trust Health Care AlphaDEX Fund (FXH) and SPDR S&P Health Care Equipment ETF (XHE).
What guidance has Penumbra issued on next quarter's earnings?: Penumbra updated its FY 2023 earnings guidance on Tuesday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.05 billion-$1.07 billion, compared to the consensus revenue estimate of $1.05 billion.

What is Adam Elsesser's approval rating as Penumbra's CEO?: 57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.
What other stocks do shareholders of Penumbra own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).
What is Penumbra's stock symbol?: Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How do I buy shares of Penumbra?: Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Penumbra's stock price today?: One share of PEN stock can currently be purchased for approximately $232.79.
How much money does Penumbra make?: Penumbra (NYSE:PEN) has a market capitalization of $8.95 billion and generates $847.13 million in revenue each year. The company earns $-2,000,000.00 in net income (profit) each year or $0.74 on an earnings per share basis.
How many employees does Penumbra have?: The company employs 3,900 workers across the globe.
How can I contact Penumbra?: Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial